180 related articles for article (PubMed ID: 37064133)
1. Clinicopathological characteristics and prognosis of early-stage HER2 low-expression breast cancer: A single-center retrospective study.
Liu CG; Li YF; Ma TY; Lv M; Lv ZD; Wang YY; Liu XP; Mao Y; Wang HB
Front Oncol; 2023; 13():1130734. PubMed ID: 37064133
[TBL] [Abstract][Full Text] [Related]
2. [Clinicopathological features and prognosis of breast cancer with human epidermal growth factor receptor 2 low expression].
Zhu XJ; Zhang H; Zhang S; Li D; Li X; Xu L; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):243-253. PubMed ID: 37042134
[TBL] [Abstract][Full Text] [Related]
3. [Clinicopathological features and prognosis of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer].
Wang Y; Zhang S; Zhang H; Liang L; Xu L; Cheng YJ; Duan XN; Liu YH; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):853-862. PubMed ID: 36241228
[TBL] [Abstract][Full Text] [Related]
4. Analysis of clinicopathological characteristics and prognostic factors of early-stage human epidermal growth factor receptor 2 (HER2)-low breast cancer: Compared with HER2-0 breast cancer.
Wu Q; Yang F; Liu Y; Zhang H; Zhang S; Xin L; Xu L
Cancer Med; 2023 Oct; 12(19):19560-19575. PubMed ID: 37772432
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological Characteristics and Prognosis of HER2-Low Early-Stage Breast Cancer: A Single-Institution Experience.
Xu H; Han Y; Wu Y; Wang Y; Li Q; Zhang P; Yuan P; Luo Y; Fan Y; Chen S; Cai R; Li Q; Ma F; Xu B; Wang J
Front Oncol; 2022; 12():906011. PubMed ID: 35785207
[TBL] [Abstract][Full Text] [Related]
6. A multicenter study of the clinicopathological characteristics and a risk prediction model of early-stage breast cancer with hormone receptor-positive/human epidermal growth factor receptor 2-low expression.
Xin L; Wu Q; Zhan C; Qin H; Xiang H; Gao M; Duan X; Liu Y; Ye J; ;
Chin Med J (Engl); 2023 Dec; 136(24):2967-2973. PubMed ID: 37822006
[TBL] [Abstract][Full Text] [Related]
7. Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients.
Chen Z; Jia H; Zhang H; Chen L; Zhao P; Zhao J; Fu G; Xing X; Li Y; Wang C
Breast Cancer Res Treat; 2023 Nov; 202(2):313-323. PubMed ID: 37639064
[TBL] [Abstract][Full Text] [Related]
8. Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: A systematic review and meta-analysis.
Ergun Y; Ucar G; Akagunduz B
Cancer Treat Rev; 2023 Apr; 115():102538. PubMed ID: 36898351
[TBL] [Abstract][Full Text] [Related]
9. Identifying clinicopathological risk factors for regional lymph node metastasis in Chinese patients with T1 breast cancer: a population-based study.
Liu G; Xing Z; Guo C; Dai Q; Cheng H; Wang X; Tang Y; Wang Y
Front Oncol; 2023; 13():1217869. PubMed ID: 37601676
[TBL] [Abstract][Full Text] [Related]
10. Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution's experience in Korea.
Park YH; Karantza V; Calhoun SR; Park S; Lee S; Kim JY; Yu JH; Kim SW; Lee JE; Nam SJ; Aktan G; Marsico M
Breast Cancer Res Treat; 2021 Oct; 189(3):653-663. PubMed ID: 34487293
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.
Zhang M; Zhang X; Zhao S; Wang Y; Di W; Zhao G; Yang M; Zhang Q
Target Oncol; 2014 Dec; 9(4):349-57. PubMed ID: 24233638
[TBL] [Abstract][Full Text] [Related]
12. A retrospective prognostic evaluation analysis using the 8th edition of the American Joint Committee on Cancer staging system for breast cancer.
Lee SB; Sohn G; Kim J; Chung IY; Lee JW; Kim HJ; Ko BS; Son BH; Ahn SH
Breast Cancer Res Treat; 2018 Jun; 169(2):257-266. PubMed ID: 29388016
[TBL] [Abstract][Full Text] [Related]
13. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
14. HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer.
Cherifi F; Da Silva A; Johnson A; Blanc-Fournier C; Abramovici O; Broyelle A; Levy C; Allouache D; Hrab I; Segura C; Morel A; Villemin M; Boscher C; Dubot-Poitelon C; Rottier P; Lequesne J; Emile G
BMC Cancer; 2022 Oct; 22(1):1081. PubMed ID: 36266623
[TBL] [Abstract][Full Text] [Related]
15. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
Yang X; Rao J; Yang W; Shui R
Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444
[TBL] [Abstract][Full Text] [Related]
17. Strong adverse effect of epidermal growth factor receptor 2 overexpression on prognosis of patients with invasive lobular breast cancer: a comparative study with invasive ductal breast cancer in Chinese population.
Wang T; Ma Y; Wang L; Liu H; Chen M; Niu R
Tumour Biol; 2015 Aug; 36(8):6113-24. PubMed ID: 25804795
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of HER2-low expression in HER2-negative breast cancer under different hormone receptor status.
Xu B; Shen J; Shen J; Wang L
Int J Clin Oncol; 2023 Apr; 28(4):543-549. PubMed ID: 36723789
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of the primary tumor site and immune indexes in patients with estrogen receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.
Song X; Ma J; Zhang H; Zhang Q
Gland Surg; 2020 Oct; 9(5):1450-1468. PubMed ID: 33224820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]